Literature DB >> 32092786

Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.

Louis Dijkstra1, Marco Garling2, Ronja Foraita1, Iris Pigeot1.   

Abstract

PURPOSE: Spontaneous reporting systems (SRSs) are used to discover previously unknown relationships between drugs and adverse drug reactions (ADRs). A plethora of statistical methods have been proposed over the years to identify these drug-ADR pairs. The objective of this study is to compare a wide variety of methods in their ability to detect these signals, especially when their detection is complicated by the presence of innocent bystanders (drugs that are mistaken to be associated with the ADR, since they are prescribed together with the drug that is the ADR's actual cause).
METHODS: Twelve methods, 24 measures in total, ranging from simple disproportionality measures (eg, the reporting odds ratio), hypothesis tests (eg, test of the Poisson mean), Bayesian shrinkage estimates (eg, the Bayesian confidence propagation neural network, BCPNN) to sparse regression (LASSO), are compared in their ability to detect drug-ADR pairs in a large number of simulated SRSs with varying numbers of innocent bystanders and effect sizes. The area under the precision-recall curve is used to assess the measures' performance.
RESULTS: Hypothesis tests (especially the test of the Poisson mean) perform best when the associations are weak and there is little to no confounding by other drugs. When the level of confounding increases and/or the effect sizes become larger, Bayesian shrinkage methods should be preferred. The LASSO proves to be the most robust against the innocent bystander effect.
CONCLUSIONS: There is no absolute "winner". Which method to use for a particular SRS depends on the effect sizes and the level of confounding present in the data.
© 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

Keywords:  innocent bystander effect; pharmacoepidemiology; pharmacovigilance; side effect; surveillance

Mesh:

Year:  2020        PMID: 32092786     DOI: 10.1002/pds.4970

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

Review 1.  Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

Authors:  Daniel B Horton; Anthony T Reder
Journal:  Neurotherapeutics       Date:  2021-08-18       Impact factor: 6.088

2.  Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems.

Authors:  Nayoung Han; Jung Mi Oh; In-Wha Kim
Journal:  Ther Clin Risk Manag       Date:  2021-08-21       Impact factor: 2.423

3.  Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow).

Authors:  Luiza Hoehl Loureiro Alves Barbosa; Alice Ramos Oliveira Silva; Ana Paula D'Alincourt Carvalho-Assef; Elisangela Costa Lima; Fabricio Alves Barbosa da Silva
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

4.  Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety.

Authors:  Bence Ágg; Péter Ferdinandy; Mátyás Pétervári; Bettina Benczik; Olivér M Balogh; Balázs Petrovich
Journal:  Drug Saf       Date:  2022-10-06       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.